Persistent dominance of serotype 3 in non-invasive pneumococcal disease in Belgium (2022-2025)
Clicks: 1
ID: 317773
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #201 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Non-invasive pneumococcal disease (NIPD) represents a substantial portion of the total pneumococcal disease burden worldwide. In this cross-sectional study, the serotype distribution for isolates originating from NIPD patients in Belgium (2022-2025) is described. Serotype 3 was the serotype with the largest NIPD burden in Belgium (n=178, 12.7%) and detailed analyses revealed that its burden was lower in infants <2 years when compared to older age groups. Pneumococcal conjugate vaccines PCV20 and PCV21 cover approximately 50% to 80%, respectively, of circulating serotypes responsible for NIPD in Belgium, which underlines the importance of improving vaccine uptake in the adult population.
| Reference Key |
openalex_W7165363744
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | I Passaris, Stéphanie Depickère, M Maex, P-J Ceyssens |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag371
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.